GRPR and colorectal adenocarcinoma: For instance, HT29 colorectal adenocarcinoma cells, which express high levels of GRPR, exhibited increased sensitivity to SP-G inhibitors, whereas PANC-1 pancreatic carcinoma cells, characterised by low GRPR expression, demonstrated minimal responsiveness both in vitro and in vivo [16].